阿伐替尼治疗伴KIT突变RUNX1::RUNX1T1阳性儿童AML的疗效与安全性
该回顾性研究纳入10例伴KIT突变的RUNX1::RUNX1T1阳性儿童AML患者,接受阿伐替尼治疗。第1周期后ORR为80%,中位随访10个月EFS率90%、OS率100%,不良反应可控,但随治疗周期延长反应率下降。
要点
- 阿伐替尼在伴KIT突变的RUNX1::RUNX1T1阳性儿童AML中第1周期ORR达80%。
- 中位随访10个月EFS率90%、OS率100%,安全性总体可控。
- 随治疗周期延长反应率下降,第3周期后ORR降至67%。
核心结论
- 阿伐替尼治疗伴KIT突变的RUNX1::RUNX1T1阳性儿童AML初期反应率良好,可获得更深分子学缓解,但随治疗时间延长反应率下降,安全性较高。
研究设计与样本
- 回顾性分析2022年9月至2025年6月北京大学人民医院儿科接受阿伐替尼治疗的伴KIT突变RUNX1::RUNX1T1阳性AML患儿共10例,男6例、女4例,中位年龄6.5岁。
主要发现
- 第1周期后ORR为80%(8/10),其中5例RUNX1::RUNX1T1融合基因水平下降≥1 log。
- 第2周期后ORR为78%(7/9),第3周期后ORR为67%(4/6)。
- 中位随访10个月,EFS率为90%,OS率为100%。
- 10例中5例在阿伐替尼治疗期间RUNX1::RUNX1T1融合基因水平升高。
- 联合化疗期间不良反应多与化疗相关,单药或联合干扰素时以1~2级血液学不良反应为主,1例出现惊厥停药对症后好转。
关键数值与推荐
- KIT突变类型:D816V 8例,D816H 1例,D816Y 1例。
- 所有患儿接受≥1个周期阿伐替尼,9例≥2个周期,6例≥3个周期。
临床怎么用
- 阿伐替尼可用于伴KIT突变的RUNX1::RUNX1T1阳性儿童AML,初期可获较高反应率并加深分子学缓解。
- 治疗中需监测RUNX1::RUNX1T1融合基因水平及不良反应,尤其注意惊厥等神经系统事件。
局限性
- 回顾性研究,样本量仅10例,随访时间中位10个月,结论需更大样本和更长随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the efficacy and safety of avapritinib in children with RUNX1::RUNX1T1-positive acute myeloid leukemia (AML) with KIT mutations. Methods: Clinical data on children with RUNX1::RUNX1T1-positive AML with KIT mutations who received avapritinib at the Department of Pediatrics, Peking University People's Hospital, from September 2022 to June 2025 were collected. The overall response rate (ORR), event-free survival (EFS), overall survival (OS), and adverse reactions of avapritinib treatment were retrospectively analyzed. Results: Ten children (6 males, 4 females) with a median age of 6.5 years were enrolled. All carried KIT mutations (D816V, n=8; D816H, n=1; D816Y, n= 1). All children completed ≥1 cycle of avapritinib; 9 received ≥2 cycles, and 6 received ≥3 cycles. After cycle 1, the ORR was 80% (8/10), with 5 children achieving ≥1 log reduction in RUNX1::RUNX1T1. The ORR was 78% (7/9) after cycle 2 and 67% (4/6) after cycle 3. With a median follow-up of 10 months, the EFS rate were 90%, and the OS rate was 100%. During avapritinib treatment, 5 of the 10 children showed elevated levels of the RUNX1::RUNX1T1. During combination avapritinib and chemotherapy, adverse events were largely attributable to chemotherapy, manifesting as hematological adverse reactions, gastrointestinal reactions, and infections, all of which improved after symptomatic treatment. When avapritinib was used alone or with interferon, toxicity was mainly associated with grade 1-2 hematological adverse reactions; one case developed convulsions and improved after drug withdrawal and symptomatic treatment. Conclusion: Avapritinib provides a favorable initial response in children with RUNX1::RUNX1T1-positive AML harboring KIT mutations, enabling deeper molecular remission; however, response rates decline with prolonged treatment. Avapritinib has a favorable safety profile. 目的: 探讨阿伐替尼治疗伴KIT突变的RUNX1::RUNX1T1阳性儿童急性髓系白血病(AML)的疗效和安全性。 方法: 收集2022年9月至2025年6月在北京大学人民医院儿科接受阿伐替尼治疗的伴KIT突变的RUNX1::RUNX1T1阳性AML患儿病例资料,回顾性分析阿伐替尼治疗总反应率(ORR)、无事件生存(EFS)率、总生存(OS)率以及不良反应。 结果: 10例AML患儿中,男6例,女4例,开始应用阿伐替尼时中位年龄6.5岁。KIT突变类型包括D816V突变8例,D816H突变1例,D816Y突变1例。所有患儿均接受≥1个周期阿伐替尼治疗,其中9例患儿接受≥2个周期阿伐替尼治疗,6例患儿接受≥3个周期阿伐替尼治疗。第1周期后,10例患儿对阿伐替尼治疗的ORR为80%(8/10),其中5例患儿RUNX1::RUNX1T1融合基因水平下降≥1 log;第2周期后ORR为78%(7/9),第3周期后ORR为67%(4/6)。中位随访时间10个月,EFS率为90%,OS率为100%。10例患儿在阿伐替尼治疗期间有5例RUNX1::RUNX1T1融合基因水平升高。阿伐替尼联合化疗期间的不良反应大多与化疗药物有关,表现为血液学不良反应以及胃肠道反应、感染等,均对症处理后好转。在单药或联合干扰素治疗期间以1~2级血液学不良反应为主,其中1例出现惊厥,停药对症处理后好转。 结论: 阿伐替尼治疗伴KIT突变的RUNX1::RUNX1T1阳性AML患儿初期具有良好的反应率,能够获得更深层次的分子学缓解,但随着治疗时间延长,反应率下降。阿伐替尼治疗具有较高的安全性。.
引用
- Zheng FY, Ding MM, Lu AD, et al. [Efficacy and safety analysis of avapritinib in children with RUNX1::RUNX1T1 positive-acute myeloid leukemia with KIT mutations]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42161658. doi:10.3760/cma.j.cn121090-20251027-00482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。